Sandoz’s Zessly (infliximab) Receives EU Approval for Gastroenterological, Rheumatological And Dermatological Diseases

 Sandoz’s Zessly (infliximab) Receives EU Approval for Gastroenterological, Rheumatological And Dermatological Diseases

Sandoz’s Zessly (infliximab) Receives EU Approval for Gastroenterological, Rheumatological And Dermatological Diseases

Shots:

  • The approval is based on non-inferiority and P-III REFLECTIONS B537-02 study results assessing Zessly vs reference drug and demonstrated meeting 1EPs with safety, efficacy and quality
  • Zessly is 3rd EC approval in 12 mos. and 6th biosimilar approval for Sandoz
  • Zessly (infliximab) is a mAb, blocks the action of tumor necrosis factor (TNF)-alpha in patients with autoimmune disorders

Click here read full press release/ article | Ref: Sandoz | Image: Princeton Forrestal Center

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post